New liposome drug takes aim at Hard-to-Treat cancers
Disease control
Not yet recruiting
This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…
Phase: PHASE1 • Sponsor: HighField Biopharmaceuticals Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC